|
[1] SHEN HQ. Primary intestinal lymphangiectasia in children[J].J Appl Clin Pediatr, 2018, 33 (7) :490-495. (in Chinese) 沈惠青.儿童原发小肠淋巴管扩张症[J].中华实用儿科临床杂志, 2018, 33 (7) :490-495.
|
|
[2] LUO X, CUI HL, CHEN DF. Pentasa in treatment of intestinal lymphangiectasia:One case report[J]. Chin J Gastroenterol Hepatol, 2018, 27 (8) :954-956. (in Chinese) 罗茜, 崔红利, 陈东风.颇得斯安治疗小肠淋巴管扩张症1例报道[J].胃肠病学和肝病学杂志, 2018, 27 (8) :954-956.
|
|
[3] ALSHIKHO MJ, TALAS JM, NOURELDINE SI, et al. Intestinal lymphangiectasia:Insights on management and literature review[J]. Am J Case Rep, 2016, 17:512-522.
|
|
[4] WANG X, JIN H, WU W. Primary intestinal lymphangiectasia manifested as unusual edemas and effusions:A case report[J]. Medicine (Baltimore) , 2016, 95 (10) :e2849.
|
|
[5] LI YM, ZHANG BL. Current research status of intestinal lymphangiectasia[J]. J Diagn Concepts Pract, 2008, 7 (1) :9-11. (in Chinese) 厉有名, 张冰凌.小肠淋巴管扩张症的研究现状[J].诊断学理论与实践, 2008, 7 (1) :9-11.
|
|
[6] YE S, ZHAN X. Research advances in primary intestinal lymphangiectasia[J/CD]. Chin J Clinicians:Electronic Edition, 2016, 10 (11) :1613-1616. (in Chinese) 叶珊, 詹学.原发性小肠淋巴管扩张症的研究进展[J/CD].中华临床医师杂志:电子版, 2016, 10 (11) :1613-1616.
|
|
[7] FILIK L, OGUZ P, KOKSAL A, et al. A case with intestinal lymphangiectasia successfully treated with slow-release octreotide[J]. Dig Liver Dis, 2004, 36 (10) :687-690.
|
|
[8] MACLEAN JE, COHEN E, WEINSTEIN M, et al. Primary intestinal and thoracic lymphangiectasia:A response to antiplasmin therapy[J]. Pediatrics, 2002, 109 (6) :1177-1180.
|
|
[9] OZEKI M, HORI T, KANDA K, et al. Everolimus for primary intestinal lymphangiectasia with protein-losing enteropathy[J]. Pediatrics, 2016, 137 (3) :e20152562.
|
|
[10] DONG J, XIN JF, HUO M, et al. Direct lymphangiography with sequential CT lymphangiography in secondary intestinal lymphangiectasia:A retrospective study[J]. J Clin Radiol, 2018, 37 (3) :419-423. (in Chinese) 董健, 信建峰, 霍萌, 等.直接淋巴管造影与CT淋巴管成像在继发性小肠淋巴管扩张症的回顾性研究[J].临床放射学杂志, 2018, 37 (3) :419-423.
|
|
[11] ZHANG Y, HAN DD, ZHAO X, et al. Long-term application of atorvastatin calcium caused liver injury:One case report[J]. Chin J Pharmacoepidemiol, 2016, 25 (8) :526-527. (in Chinese) 张莹, 韩东冬, 赵昕, 等.长期应用阿托伐他汀钙致肝损伤1例[J].药物流行病学杂志, 2016, 25 (8) :526-527.
|
|
[12] ZENG HQ, ZHANG Q, PENG WX. Mechanism of atorvastatin-induced liver injury[J]. ADRJ, 2012, 14 (4) :232-236. (in Chinese) 曾含清, 张琼, 彭文兴.阿托伐他汀致肝损伤的机制[J].药物不良反应杂志, 2012, 14 (4) :232-236.
|
|
[13] LIU MH, CHEN CZ. Cost analysis of liver injury caused by atorvastatin in 11 patients[J]. Strait Pharm J, 2018, 30 (2) :265-268. (in Chinese) 刘敏惠, 陈崇泽.阿托伐他汀致11例患者肝损伤及费用分析[J].海峡药学, 2018, 30 (2) :265-268.
|
|
[14] PENG JL, MA GW, YU ML, et al. Experimenrtal study of liver injury caused by lovastatin combined with isoniazid, rifampicin and pyrazinamide in rats[J]. Anhui Med Pharm J, 2017, 21 (12) :2157-2163. (in Chinese) 彭江丽, 马国伟, 喻明丽, 等.洛伐他汀联合异烟肼、利福平、吡嗪酰胺致大鼠肝损伤的实验研究[J].安徽医药, 2017, 21 (12) :2157-2163.
|
DownLoad: